41100-52-1 Memantine HCl AKSci J10287
 
 
Loading Please Wait...
  J10287    
Memantine HCl
, 99% (GC), powder
 



IDENTITY
CAS Number:41100-52-1
MDL Number:MFCD00214336
MF:C12H22ClN
MW:215.76
EINECS:255-219-6
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:99% (GC), powder
Physical Form (at 20°C):Solid
Melting Point:292°C
Long-Term Storage:Store long-term in a cool, dry place
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Solubility:Water: 1mg/mL
Application(s):NMDA receptor antagonist, non-competitive 5-HT3 receptor antagonist, nicotinic acetylcholine recepto
Form:HCl salt
Research Area:Generic drug

REVIEW

 Memantine exerts its action through uncompetitive NMDA receptor antagonism, binding preferentially to the NMDA receptor-operated cation channels. Prolonged increased levels of glutamate in the brain of demented patients are sufficient to counter the voltage-dependent block of NMDA receptors by Mg2+ ions and allow continuous influx of Ca2+ ions into cells, ultimately resulting in neuronal degeneration. Studies suggest that memantine binds more effectively than Mg2+ ions at the NMDA receptor, and thereby effectively blocks this prolonged influx of Ca2+ ions through the NMDA channel whilst preserving the transient physiological activation of the channels by higher concentrations of synaptically released glutamate. Thus memantine protects against chronically elevated concentrations of glutamate. Memantine also has antagonistic activity at the type 3 serotonergic (5-HT3) receptor with a potency that is similar to that at the NMDA receptor, and lower antagonistic activity at the nicotinic acetylcholine receptor. This drug has no affinity for γ-aminobutyric acid (GABA), benzodiazepine, dopamine, adrenergic, histamine, or glycine receptors or for voltage-dependent calcium, sodium, or potassium channels

REFERENCES
[1]'Cacabelos R, Takeda M, Winblad B: The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer''s disease. Int J Geriatr Psychiatry. 1999 Jan;14(1):3-47. '
[2] 'Rogawski MA, Wenk GL: The neuropharmacological basis for the use of memantine in the treatment of Alzheimer''s disease. CNS Drug Rev. 2003 Fall;9(3):275-308. '
[3] 'Robinson DM, Keating GM: Memantine: a review of its use in Alzheimer''s disease. Drugs. 2006;66(11):1515-34. '
[4] Rogawski MA: Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents-toward an understanding of their favorable tolerability. Amino Acids. 2000;19(1):133-49.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


Current as of February 2, 2025


Download SDS Request COA

All products are stocked and shipped from the SF Bay, California, USA via FedEx, UPS or DHL.
All batches backed with full quality assurance.
⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.



CATEGORIES

 APIs and Bioactives > Alzheimer's


PubChem